TAG:
diagnostic laboratory
Congress’ New SGR Law Has Mixed News for Labs
By Joseph Burns | From the Volume XXI No. 5 – April 7, 2014 Issue
CEO SUMMARY: Once again, the lab industry faces a mixed bag following passage of a new law by Congress last week. Besides the one-year fix for the SGR, H.R. 4302 also has language that may defer adjustments to Medicare Part B lab test fees until 2017 and creates a new procedure for Medica…
New Federal Law Changes How CMS Sets Lab Prices
By Robert Michel | From the Volume XXI No. 5 – April 7, 2014 Issue
CEO SUMMARY: CMS wanted more power to cut the prices it pays for clinical lab testing. A significant part of the lab industry wanted more transparency and consistency in how CMS established coverage guidelines and prices for new lab tests. Congress appears to have attempted to craft a law…
ACLA, CAP Comment on Final 2014 Medicare Rules
By Joseph Burns | From the Volume XX, No. 16 – December 2, 2013 Issue
CEO SUMMARY: On November 27, as the nation prepared for the Thanksgiving holiday, the federal Centers for Medicare & Medicaid Services (CMS) announced the long-awaited final rules for 2014. Early analysis of the 1,300 pages of rules CMS released indicates that the agency moderated one…
Alberta Lab RFP, FTC, LabMD Biodiagnostic Lab Services Guilty Pleas
By Robert Michel | From the Volume XX No. 13 – September 30, 2013 Issue
ALBERTA PROVINCE MAY SOON BID $3 BILLION CLINICAL LAB CONTRACT NEWS LEAKED ON SEPTEMBER 19 that Alberta Health Services (AHS) is preparing to issue a request for proposal (RFP) to select a company to build a state-of-the clinical laboratory facility to serve…
Attorneys for CAP Say CMS Fee Proposals Illegal
By Joseph Burns | From the Volume XX No. 12 – September 9, 2013 Issue
CEO SUMMARY: In its comments about a proposal to change the way CMS pays for clinical laboratory and pathology services, the College of American Pathologists (CAP) said that CMS is using faulty assumptions. CAP further commented that the CMS proposal to cap physician fee schedule payments…
Reporters & Investigators Target Fraud in Pain Management Market
By Joseph Burns | From the Volume XX No. 11 – August 13, 2013 Issue
PAIN MANAGEMENT IS COMING under increased scrutiny by law enforcement officials and government regulators. Even the national media have begun to notice the fraud and abuse that is rampant in this rapidly-expanding sector of healthcare. Many pathologists and clinical laboratory managers will welcome …
Feds Nail Doctors for Accepting Bribes from Labs
By R. Lewis Dark | From the Volume XX No. 10 – July 29, 2013 Issue
HALLELUJAH! FOUR DOCTORS IN NEW JERSEY HAVE PLEADED GUILTY to federal criminal charges of accepting bribes from Biodiagnostic Laboratory Services (BLS), the clinical lab company in Parsippany, New Jersey. Can any of you remember the last time that a federal prosecutor pursued crimina…
Four Docs Plead Guilty In N.J. Lab Bribery Case
By Joseph Burns | From the Volume XX No. 10 – July 29, 2013 Issue
CEO SUMMARY: As of July 24, four New Jersey doctors had pleaded guilty to federal criminal charges. Each of the doctors accepted bribes in exchange for referring patient lab testing to Biodiagnostic Laboratory Services (BLS) of Parsippany, New Jersey. This landmark criminal prosecution in…
OIG Tells CMS It Could Save $910 Million on Lab Test Costs
By Robert Michel | From the Volume XX No. 8 – June 17, 2013 Issue
IT IS ONE MORE POWERFUL SIGN of the changing times. Last week, the Office of the Inspector (OIG) publicly released a study it had done of the prices paid for lab testing and how the Medicare program could use this information to reduce the cost of Part B clinical laboratory testing. It was The W…
Ampersand Buys Calloway Labs, Enters Pain Management Market
By Robert Michel | From the Volume XIX No. – October 8, 2012 Issue
URINE DRUG TESTING for pain management may be a challenging business for clinical labs given that compliance officers in the states and in the federal government have successfully pursued lab compliance abuses in this line of business in recent years. Now comes news that private equity firm …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized